Free tool
FAERS Monitor: Astepro Allergy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213872 or its brand name (Astepro Allergy, Azelastine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,427
Serious
646
45% of reports
Hospitalization
278
Death reported
76
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective104
- fatigue100
- headache81
- nausea74
- diarrhoea73
- dizziness60
- dyspnoea54
- pneumonia52
- cough50
- pain50
- vomiting49
- malaise47
- somnolence47
- asthenia46
- pruritus41
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 13 |
| 2005 | 6 |
| 2006 | 8 |
| 2007 | 15 |
| 2008 | 25 |
| 2009 | 22 |
| 2010 | 72 |
| 2011 | 46 |
| 2012 | 40 |
| 2013 | 6 |
| 2014 | 17 |
| 2015 | 62 |
| 2016 | 112 |
| 2017 | 111 |
| 2018 | 140 |
| 2019 | 162 |
| 2020 | 182 |
| 2021 | 133 |
| 2022 | 5 |
| 2023 | 34 |
| 2024 | 5 |
| 2025 | 195 |
| 2026 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,732 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| somnolenceSignal | 47 | 3.4 | 2.6 | 80 |
| coughSignal | 50 | 2.6 | 2.0 | 49 |
| pneumoniaSignal | 52 | 2.4 | 1.8 | 40 |
| headache | 81 | 1.9 | 1.5 | 35 |
| fatigue | 100 | 1.9 | 1.6 | 43 |
| asthenia | 46 | 1.8 | 1.4 | 16 |
| dizziness | 60 | 1.8 | 1.4 | 20 |
| diarrhoea | 73 | 1.7 | 1.3 | 19 |
| malaise | 47 | 1.6 | 1.2 | 10 |
| pruritus | 41 | 1.6 | 1.2 | 8 |
| vomiting | 49 | 1.5 | 1.2 | 9 |
| dyspnoea | 54 | 1.4 | 1.1 | 6 |
| nausea | 74 | 1.4 | 1.1 | 8 |
| pain | 50 | 1.2 | 0.9 | 2 |
| drug ineffective | 104 | 1.2 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.